The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
Official Title: Prospective Registry of Iclusig® (Ponatinib) Used in Clinical Practice for the Treatment of Patients With Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
Study ID: NCT03678454
Brief Summary: This prospective registry is initiated to follow up on the use of Iclusig® in patients with CML or Ph+ ALL in routine practice in Belgium.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
ZNA Stuyvenberg, Antwerpen, , Belgium
UZ Antwerpen, Antwerpen, , Belgium
AZ Klina, Brasschaat, , Belgium
AZ St-Jan Brugge, Brugge, , Belgium
Institut Jules Bordet, Brussels, , Belgium
CHU Brugmann, Brussels, , Belgium
Hopital Erasme, Brussels, , Belgium
UZ Brussel, Brussels, , Belgium
Clinique universitaires Saint-Luc, Brussels, , Belgium
Ziekenhuis Oost Limburg (ZOL), Gent, , Belgium
Hopital Jolimont, Haine-Saint-Paul, , Belgium
Jessa Ziekenhuis, Hasselt, , Belgium
AZ Groeninge, Kortrijk, , Belgium
UZ Leuven, Leuven, , Belgium
CHU Sart Tilman Liège, Liège, , Belgium
CHU Charleroi Vésale, Montigny-le-Tilleul, , Belgium
AZ Turnhout St-Elisabeth, Turnhout, , Belgium
CHR La Tourelle, Verviers, , Belgium
CHU/UCL Namur Mont-Godinne, Yvoir, , Belgium
Name: Michael Beck, PhD
Affiliation: Incyte Biosciences Benelux
Role: STUDY_DIRECTOR